Prevenor 13 (multidose) – (4,800) at Dr. Essa Lab

Prevenor 13 (multidose) – (4,800) at Dr. Essa Lab

Prevenor 13 (multidose) – (4,800) at Dr. Essa Lab is a highly specialized immunization service designed to protect infants, young children, older adults, and high-risk individuals against invasive pneumococcal disease (IPD) and pneumonia caused by the bacterium Streptococcus pneumoniae. Streptococcus pneumoniae is a highly virulent pathogen responsible for severe, life-threatening infections, including meningitis, bacteremia, sepsis, and severe community-acquired pneumonia, as well as non-invasive but highly prevalent infections such as acute otitis media and sinusitis. The Prevenor 13 vaccine, also known globally as PCV13 (Pneumococcal Conjugate Vaccine), is formulated to provide active immunization against thirteen of the most prevalent and serologically distinct pneumococcal serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F.

The multidose formulation offered at Dr. Essa Lab represents a critical public health tool, particularly in densely populated urban centers like Karachi, Pakistan, where infectious diseases pose a continuous challenge. This vaccine works by introducing purified capsular polysaccharides from each of the thirteen serotypes, which are individually conjugated to a non-toxic diphtheria carrier protein known as CRM197. This conjugation process is scientifically vital; plain polysaccharide vaccines do not reliably stimulate the immature immune systems of infants under two years of age. By conjugating the polysaccharides to the CRM197 carrier protein, the vaccine converts a T-cell independent immune response into a T-cell dependent response. This stimulates helper T-cells, induces robust immunological memory, and ensures long-term, high-affinity antibody production even in newborn infants and immunocompromised individuals.

At Dr. Essa Lab, the administration of Prevenor 13 (multidose) – (4,800) is conducted under strict clinical protocols. The multidose designation indicates that the vaccine vial contains multiple doses, requiring meticulous aseptic technique and precise cold-chain management to maintain vaccine potency and prevent contamination. Dr. Essa Lab utilizes state-of-the-art medical refrigeration systems to ensure the vaccine is consistently stored at the manufacturer-recommended temperature of 2°C to 8°C. This guarantees that every dose administered retains its full immunogenic potential, providing maximum protective efficacy to the patient.

Clinical Procedure: What to Expect

Patient Preparation

Proper patient preparation is essential to ensure the safety and efficacy of the Prevenor 13 (multidose) – (4,800) immunization at Dr. Essa Lab. Patients, parents, or guardians should adhere to the following clinical guidelines prior to the appointment:

• Medical History Review: Prepare a complete medical history, including any known allergies, previous vaccine reactions, history of Guillain-Barré syndrome, or bleeding disorders.
• Acute Illness Assessment: If the patient is experiencing a moderate-to-severe acute illness, with or without a fever, it is generally recommended to postpone the vaccination until the acute phase has resolved. Mild illnesses, such as a common cold or low-grade fever, do not contraindicate vaccination.
• Medication Disclosure: Inform the healthcare provider of all current medications, especially immunosuppressive therapies (such as systemic corticosteroids, chemotherapy, or radiation therapy) which may reduce the immune response to the vaccine.
• Coagulation Status: Patients with bleeding disorders, such as hemophilia, or those taking anticoagulant medications (e.g., warfarin) must inform the clinical staff, as special precautions are required for intramuscular injections to prevent hematoma formation.
• Documentation: Bring any previous immunization records or vaccination cards to ensure the dose is correctly logged into the patient’s medical history.

During the Procedure

The administration of Prevenor 13 (multidose) – (4,800) at Dr. Essa Lab is performed by highly trained, certified nursing professionals who follow strict clinical standards:

• Aseptic Preparation: The healthcare professional will perform hand hygiene and prepare the injection site using a sterile alcohol swab, allowing it to air dry completely.
• Vaccine Inspection: The nurse will visually inspect the multidose vial for any particulate matter or discoloration and verify that the vaccine has been stored under proper cold-chain conditions. The vial is shaken vigorously to obtain a homogenous, white, cloudy suspension.
• Dose Withdrawal: Using a sterile, single-use syringe and needle, the nurse will precisely withdraw a 0.5 mL dose from the multidose vial, adhering to strict aseptic techniques to prevent contamination of the remaining doses.
• Patient Positioning: For infants and toddlers, the vaccine is administered intramuscularly into the anterolateral aspect of the thigh (vastus lateralis muscle). For older children and adults, the vaccine is injected into the deltoid muscle of the upper arm. The patient is positioned comfortably, and infants are securely but gently held by their parent or guardian.
• Injection: The needle is inserted at a 90-degree angle to ensure deep intramuscular delivery. The vaccine is injected slowly to minimize localized tissue discomfort.
• Post-Injection Care: Gentle pressure is applied to the injection site with a sterile cotton ball. Rubbing the site is avoided. A small adhesive bandage may be applied.
• Observation Period: The patient is required to remain in the waiting area under clinical observation for 15 to 30 minutes post-injection to monitor for any immediate hypersensitivity or anaphylactic reactions.

When is a Prevenor 13 (multidose) – (4,800) Performed?

Routine Pediatric Immunization

The primary clinical indication for Prevenor 13 is routine active immunization in infants and toddlers. Pediatricians recommend this vaccine starting as early as 6 weeks of age to protect infants during their most vulnerable developmental stages. The standard pediatric schedule typically consists of a primary series of three doses at 2, 4, and 6 months of age, followed by a booster dose at 12 to 15 months of age. This structured regimen ensures the development of robust, long-lasting antibody titers during early childhood when the risk of contracting invasive pneumococcal disease is statistically highest.

Adults Aged 65 and Older

As the human immune system undergoes immunosenescence with age, older adults become increasingly susceptible to severe pneumococcal infections. Physicians recommend Prevenor 13 for adults aged 65 and older to bolster their humoral immunity against the 13 vaccine-specific serotypes. Immunization in this demographic significantly reduces the incidence of vaccine-type community-acquired pneumonia and invasive pneumococcal bacteremia, thereby decreasing hospitalization rates and mortality associated with respiratory infections in the elderly population.

Immunocompromised Individuals

Patients with compromised immune systems are at an extraordinarily high risk of developing severe, invasive pneumococcal infections. Clinicians strongly recommend Prevenor 13 for individuals with congenital or acquired immunodeficiencies, HIV infection, chronic renal failure, nephrotic syndrome, leukemia, lymphoma, Hodgkin disease, generalized malignancy, or those undergoing immunosuppressive therapy. Additionally, patients with functional or anatomic asplenia (including sickle cell disease) require this vaccine, as the spleen plays a crucial role in clearing encapsulated bacteria like Streptococcus pneumoniae from the bloodstream.

Patients with Chronic Medical Conditions

Underlying chronic illnesses can severely compromise a patient’s physiological reserves, making pneumococcal infections far more dangerous. Prevenor 13 is indicated for patients aged 2 through 64 with chronic cardiovascular disease (e.g., congestive heart failure, cardiomyopathies), chronic pulmonary disease (including chronic obstructive pulmonary disease and asthma), diabetes mellitus, chronic liver disease (including cirrhosis), or cerebrospinal fluid (CSF) leaks and cochlear implants. These conditions compromise natural mucosal barriers or systemic defenses, making vaccination a critical preventive measure.

Prevention of Pneumococcal Meningitis and Bacteremia

Pneumococcal meningitis is a medical emergency with high rates of neurological sequelae and mortality. Similarly, pneumococcal bacteremia can rapidly progress to septic shock and multi-organ failure. Physicians prescribe Prevenor 13 as a primary preventive strategy to induce mucosal and systemic IgG antibodies that block the hematogenous spread of Streptococcus pneumoniae. By preventing the bacteria from colonizing the nasopharynx and entering the bloodstream, the vaccine effectively thwarts the development of these devastating invasive clinical conditions.

What Does a Prevenor 13 (multidose) – (4,800) Detect?

As an active immunizing agent, Prevenor 13 (multidose) – (4,800) does not “detect” active pathogens or diagnose diseases. Instead, it stimulates the patient’s immune system to produce protective antibodies and immunological memory against specific bacterial targets. The clinical efficacy and protective scope of this vaccine are evaluated based on its ability to prevent infections caused by the following specific serotypes and clinical entities:

• Streptococcus pneumoniae Serotype 1: A major cause of invasive disease and empyema in children and young adults.
• Streptococcus pneumoniae Serotype 3: Associated with severe necrotizing pneumonia, empyema, and high mortality rates.
• Streptococcus pneumoniae Serotype 4: Frequently isolated in adult bacteremic pneumonia cases.
• Streptococcus pneumoniae Serotype 5: Highly prevalent in invasive pneumococcal disease in developing nations.
• Streptococcus pneumoniae Serotype 6A: Important for cross-protection and prevention of antibiotic-resistant strains.
• Streptococcus pneumoniae Serotype 6B: Historically associated with high rates of multidrug resistance.
• Streptococcus pneumoniae Serotype 7F: A highly invasive serotype associated with severe bacteremia.
• Streptococcus pneumoniae Serotype 9V: Commonly linked to pediatric meningitis and penicillin resistance.
• Streptococcus pneumoniae Serotype 14: The most common serotype causing invasive disease in young children globally.
• Streptococcus pneumoniae Serotype 18C: Frequently associated with pediatric bacteremia and otitis media.
• Streptococcus pneumoniae Serotype 19A: A highly aggressive, frequently multidrug-resistant serotype causing severe otitis media and invasive disease.
• Streptococcus pneumoniae Serotype 19F: Associated with persistent middle ear infections and vaccine-evading strains.
• Streptococcus pneumoniae Serotype 23F: A major contributor to meningitis and localized respiratory tract infections.
• Invasive Pneumococcal Disease (IPD): Prevention of systemic infections where bacteria are isolated from normally sterile sites.
• Pneumococcal Meningitis: Prevention of life-threatening inflammation of the meninges covering the brain and spinal cord.
• Pneumococcal Bacteremia: Prevention of viable bacteria circulating in the bloodstream, leading to sepsis.
• Bacteremic Pneumonia: Prevention of severe lung infection accompanied by bloodstream invasion.
• Community-Acquired Pneumonia (CAP): Reduction in the incidence of non-invasive, vaccine-type lobar pneumonia.
• Acute Otitis Media (AOM): Prevention of painful middle ear infections in infants and young children.
• Sinusitis: Prevention of secondary bacterial sinus infections caused by vaccine-specific serotypes.
• Diphtheria Carrier Protein (CRM197) Immunogenicity: Evaluation of the vaccine’s ability to recruit helper T-cells.
• Humoral Immune Response: Stimulation of serotype-specific IgG antibodies measurable via ELISA.
• Opsonophagocytic Activity (OPA): Induction of functional antibodies that facilitate the phagocytosis and killing of pneumococci.
• Mucosal Immunity: Reduction of nasopharyngeal carriage of vaccine-type pneumococci, contributing to herd immunity.
• Immunological Memory: Generation of memory B-cells for rapid, high-titer antibody production upon future pathogen exposure.

Turnaround Time and Report Access at Dr. Essa Lab

At Dr. Essa Lab, the administration of Prevenor 13 (multidose) – (4,800) is documented immediately to ensure accurate medical records. Upon successful administration of the vaccine, patients or guardians are provided with an official, physical immunization card. This card details the vaccine name, manufacturer, batch or lot number, date of administration, injection site, and the signature of the administering clinician. This physical record is essential for pediatric school admissions, international travel, and tracking subsequent booster doses.

In addition to the physical card, Dr. Essa Lab integrates all vaccination records into its secure digital patient portal. Patients can access their immunization history online through the official Dr. Essa Lab website or mobile application. The digital record is typically updated within a few hours of the procedure, allowing patients to view, download, or print their verified vaccination certificates at their convenience. This seamless digital integration ensures that your vital health records are always secure, accessible, and easily shareable with your primary care physician or specialist.

Prevenor 13 (multidose) – (4,800) Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Vaccine Serotype Coverage	Induction of protective IgG antibodies against all 13 vaccine serotypes.	Failure to develop protective antibody titers (non-responders).
Injection Site Reaction	Mild, transient erythema, swelling, or tenderness resolving within 48 hours.	Severe local reaction, persistent induration, sterile abscess, or cellulitis.
Systemic Post-Vaccination State	Normal body temperature or mild, self-limiting low-grade fever (<38.5°C).	High-grade fever (>39°C), febrile seizures, or prolonged inconsolable crying.
Immune System Status	Immunocompetent response with robust T-cell dependent B-cell activation.	Blunted immune response due to underlying congenital or acquired immunodeficiency.
Hypersensitivity Assessment	No immediate or delayed systemic allergic reactions observed.	Immediate hypersensitivity, urticaria, bronchospasm, or anaphylactic shock.
Cold Chain Integrity	Vaccine maintained consistently between 2°C and 8°C prior to administration.	Exposure to freezing or high temperatures, leading to protein denaturation.
Dose Volume and Route	Precise 0.5 mL administered via deep intramuscular injection.	Inadvertent subcutaneous administration, potentially reducing immunogenicity.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for Prevenor 13 (multidose) – (4,800)?

• Experienced Healthcare Professionals: Administered by certified, highly trained nursing staff specializing in pediatric and adult immunizations.
• Strict Cold Chain Management: Advanced medical refrigeration systems ensure the vaccine is stored at optimal temperatures to preserve maximum potency.
• ISO-Certified Standards: Dr. Essa Lab adheres to rigorous international quality control and safety standards across all branches.
• Patient-Focused Care: A compassionate, child-friendly environment designed to minimize anxiety and ensure a comfortable patient experience.
• Convenient Locations: Multiple easily accessible branches across Karachi and other major cities, making healthcare highly accessible.
• Seamless Digital Records: Instant access to your verified vaccination certificate and history via the secure Dr. Essa Lab online portal.
• Aseptic Clinical Environment: Strict adherence to infection control protocols and sterile single-use medical supplies for every procedure.
• Commitment to Accurate Diagnosis and Prevention: Over three decades of trusted diagnostic and preventive healthcare services in Pakistan.